Ann: Appendix 4D and Half Year Accounts, page-65

From the 2016 FY annual report

Pharmaceutical Processing Gelpell European Sales
During FY2016, MMJ continued to grow its pharmaceutical processing division, with a particular focus on boosting the sales of Satipharm products throughout regulated markets throughout Europe, with the Company’s first revenues generated through the sale of its CBD Capsules.
The Company recorded revenue of A$255,340 for the year ending 30 June 2016 which were lower than originally forecast due to transaction processor, Paypal, suspending all Satipharm accounts. The Company overcame this challenge by partnering with UK supplement distributor, Prima Sport, who are now selling 10 mg and 100 mg Satipharm CBD Gelpell Gastro resistant Microgel Capsules via a dedicated online store at www.premiumcbd.co.uk in order to test a direct internet sales model.

Since then have faced some 'regulatory hurdles' that have recently been starting to clear up.

Just some background, it's up to the individual whether they invest.